Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PREDICTIVE ONCOLOGY INC.

(POAI)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
0.6073 USD   +5.62%
02/06Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
AQ
02/03Predictive Oncology Inc. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
02/03Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

12/06/2022 | 09:25am EST

Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts.

Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (Nasdaq: GRTS).

Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named inventor on multiple patents and co-author on several peer-reviewed publications, he brings an awareness and insight to Predictive Oncology that will be instrumental as the company moves forward with its growth plans.

Given his deep understanding of the biopharma landscape and his years of experience launching innovative platforms that have now been run on hundreds of thousands of patients with more than 20 FDA approvals, Matthew is both a logical and strategic addition to our Board,' noted Raymond F. Vennare, Predictive Oncology Chief Executive Officer and Chairman of the Board. 'In the business of drug discovery, relationships, reputation and industry reach are invaluable attributes, all of which Matthew possesses.'

Before joining Gritstone, Dr. Hawryluk served as Vice President of Corporate and Business Development at Foundation Medicine, Inc., a public molecular information company (subsequently acquired by Roche), and before then assumed roles in business development, marketing and product management across multiple divisions of Thermo Fisher Scientific, Inc. In addition to his Board role with Predictive Oncology, Dr. Hawryluk serves as an Advisory Board Member of PathAI, Inc.

People often talk about developing a strategy for a company to succeed, but it is so much more than that. You have to implement and execute on that plan as well,' said Dr. Hawryluk. 'Predictive Oncology has a forward-thinking plan; it has a bold vision and it has a sound strategy. I share that vision and am excited to be a part of that plan.'

Dr. Hawryluk holds a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine, an M.B.A. from Carnegie Mellon University's Tepper School of Business and B.S. from the University of Notre Dame.

About Predictive Oncology

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a biobank of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials.

Contact:

Theresa Ferguson

Tel: (630) 566-2003

Email: tferguson@predictive-oncology.com

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'would,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading 'Risk Factors' in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
GRITSTONE BIO, INC. -3.34% 3.18 Delayed Quote.-7.83%
PREDICTIVE ONCOLOGY INC. 5.62% 0.6073 Delayed Quote.98.08%
All news about PREDICTIVE ONCOLOGY INC.
02/06Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
AQ
02/03Predictive Oncology Inc. : Change in Directors or Principal Officers, Financial Statements..
AQ
02/03Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
AQ
02/03Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer
CI
01/12Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Onco..
GL
01/12Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Bo..
CI
2022Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive O..
AQ
2022Distinguished Innovator in Genomics Joins theáScientific Advisory Board of Predictive O..
GL
2022Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company'..
CI
2022Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to t..
AQ
More news
Analyst Recommendations on PREDICTIVE ONCOLOGY INC.
More recommendations
Financials (USD)
Sales 2022 1,60 M - -
Net income 2022 -22,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,96x
Yield 2022 -
Capitalization 47,8 M 47,8 M -
Capi. / Sales 2022 29,9x
Capi. / Sales 2023 3,23x
Nbr of Employees 31
Free-Float 95,9%
Chart PREDICTIVE ONCOLOGY INC.
Duration : Period :
Predictive Oncology Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PREDICTIVE ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,61 $
Average target price 5,00 $
Spread / Average Target 723%
EPS Revisions
Managers and Directors
Raymond F. Vennare Chairman & Chief Executive Officer
Robert L. Myers Chief Financial Officer
Julia Kirshner Chief Scientific Officer
Lawrence J. DeLucas Senior VP-Operations
Daniel E. Handley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PREDICTIVE ONCOLOGY INC.98.08%48
ABBOTT LABORATORIES1.82%194 914
MEDTRONIC PLC12.07%115 859
BECTON, DICKINSON AND COMPANY-1.63%69 794
DEXCOM, INC.-4.25%41 882
HOYA CORPORATION12.12%38 781